Form 4: IRADIMED CEO Sells $487K in Shares

IRADIMED Corp's CEO, President, and Chairman, Roger E. Susi, sold 5,000 shares of common stock for approximately $487,268 through a pre-arranged 10b5-1 trading plan.

Summary

• Roger E. Susi, CEO, President, and Chairman of IRADIMED Corp, reported the sale of 5,000 shares of common stock.
• The sales occurred on January 12, 2026, and were executed under a Rule 10b5-1 trading plan adopted on June 16, 2025.
• The shares were sold in two separate transactions: 4,888 shares at a weighted average price of $97.43 and 112 shares at a weighted average price of $98.15.
• The total value of the shares sold is approximately $487,268.64.
• Following these transactions, Roger E. Susi indirectly beneficially owns 2,272,500 shares through the Phillip Susi 2008 Dynasty Trust, 162,950 shares through the Roger E. Susi Revocable Trust, and 2,062,500 shares through the Matthew Susi 2008 Dynasty Trust (for which he disclaims beneficial ownership except for pecuniary interest).

Sentiment

Score: 4

Explanation: While the sale was pre-planned under a 10b5-1 plan, a significant insider sale by the CEO, President, and Chairman can still be perceived negatively by the market, leading to a slightly bearish sentiment.

Positives

• The sales were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment rather than an immediate reaction to new information.

Negatives

• A significant insider sale by the CEO, President, and Chairman could be perceived negatively by investors, potentially signaling a lack of confidence or a desire to diversify personal holdings.
• The sale of 5,000 shares represents a reduction in the indirect holdings of a key executive.

Risks

• Potential negative investor sentiment due to the insider sale by a top executive.
• The sale could be misinterpreted as a signal of future underperformance, despite being part of a pre-planned trading arrangement.

Industry Context

This Form 4 filing reports a routine insider transaction under a pre-arranged trading plan, which is common practice for executives to manage their equity holdings and personal finances. It does not inherently reflect broader industry trends or competitive positioning.

Related Party Transactions

• Roger E. Susi's indirect beneficial ownership includes shares held by the Phillip Susi 2008 Dynasty Trust, Roger E. Susi Revocable Trust, and Matthew Susi 2008 Dynasty Trust. The sales were from the Phillip Susi 2008 Dynasty Trust.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially impacting stock price.
• Employees: No direct impact mentioned.
• Customers/Suppliers/Creditors: No direct impact mentioned.

Key Dates

Recommendation

The sale by the CEO, President, and Chairman, while significant in value, was executed under a pre-arranged 10b5-1 trading plan. This suggests a planned diversification or liquidity event rather than a reaction to new negative company-specific information. Given the pre-planned nature, it doesn't necessarily warrant a 'sell' recommendation, but it also doesn't provide a strong 'buy' signal. A 'hold' recommendation is appropriate to observe future company performance and market reaction.

Keywords

IRADIMED Corp, IRMD, Roger E. Susi, Insider Sale, Form 4, SEC Filing, 10b5-1 Plan, Stock Transaction, CEO, Chairman, Director, Beneficial Ownership